If tocilizumab and corticosteroids fail to control CRS, siltuximab (IL-6 antagonist) or anakinra (IL-1 receptor antagonist) could be considered, but limited clinical data are available for isolated CRS, in contrast to CRS associated with ICANS [38]. Here, IL6 is linked to congenital rubella syndrome.